Industry Veteran, Dr. John Faessel, Provides Additional Commentary on Protectus Safety Syringe and Explains Benefits of Company’s Recent International Patent-Pending Status
E-18 Corp. (OTCBB:ETEN), through its wholly owned subsidiary, SquareOne Medical, Inc., doing business as Protectus Medical Devices ("Protectus Medical Devices"), today announces the release of a SmallcapInsights.com article by industry veteran, Dr. John Faessel.
Entitled “UPDATE: A Truly Unique ‘Safe Needle,’” Dr. Faessel guides readers through the enormous opportunity for the Protectus Safety Syringe as the sole safety syringe that automatically self-sheaths. This update delves into the tolls the healthcare system faces due to accidental needlesticks, as well as the international opportunities for the Protectus Safety Syringe based on the Company’s recent international patent-pending status.
From the article:
“Needle penetrations can lead to the transmission of more than 20 bloodborne viruses, including HIV, hepatitis B and hepatitis C, from the source person to the healthcare worker. An estimated 600,000 to 1 million reported accidental injuries from conventional needles and sharps occur annually in the United States.”
Dr. Faessel goes on to say, “On 8-27-2009 ETEN announced the completion of an international patent filing for its revolutionary self-sheathing medical safety syringe technology. With over 30 billion syringes used annually around the world, including an estimated 8 billion units in the U.S. alone, the market for a truly safe syringe is indeed staggering. This international patent now paves the way for even greater opportunities abroad.”
A link to this article is available on the SmallcapInsights.com website: http://www.smallcapinsights.com.
The Protectus Medical Safety Syringe is designed to significantly reduce or eliminate accidental needlestick injuries that have plagued the healthcare workplace for decades. More information about Protectus Medical Devices may be found at the Company's corporate website at www.protectusmedical.com.
About E-18 Corp.
E-18 Corp., through its wholly owned subsidiary, SquareOne Medical, Inc., doing business as Protectus Medical Devices, develops and markets innovative safety medical percutaneous devices that, collectively, have the potential to dramatically reduce needlestick injuries for medical professionals worldwide. In the nearly $5 billion global hypodermic syringe market, the Protectus Safety Syringe, the Company's lead product, is the only fully automatic, self-sheathing hypodermic safety syringe that currently meets the functional definition of "Self-Sheathing" mandated by the U.S. Federal Government. None of the manufacturers of other devices on the market can make this claim. Protectus Medical Devices has successfully patented its automatic, self-sheathing hypodermic safety syringe product, and, based on the results of full comparison clinical trials, the Protectus Safety Syringe (formerly the SquareOne Safety Syringe) has received the required 510(k) permission from the U.S. FDA to manufacture and market the device in the U.S. More information about the Company may be found at www.protectusmedical.com.
Forward-Looking Statements
Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of E-18 Corp. can be found in the filings of E-18 Corp. with the U.S. Securities and Exchange Commission.
SEC Section 17(b) Disclosure: SmallcapInsights.com is a wholly owned subsidiary of Trilogy Capital Partners, Inc. (“Trilogy”). Trilogy has been engaged by E-18 Corp. ("ETEN") to provide investor relations services for compensation including a monthly retainer of $10,000 for an initial twelve month term and 450,000 shares of restricted common stock of ETEN, to be distributed in equal monthly installments over a six month period.
Contacts:
Company Contact:
E-18 Corp.
John Salstrom, President
and CEO
1-800-778-8438
moreinfo@protectusmedical.com
or
Financial
Communications Contact:
Trilogy Capital Partners
Darren
Minton, Vice President
Toll-free: 800-592-6067
info@trilogy-capital.com
